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We investigated the activity of irinotecan given with a more convenient modiﬁed bimonthly de Gramont regimen of bolus and
infusional 5-ﬂuorouracil [IrMdG] in advanced or metastatic colorectal cancer in the ﬁrst and second line setting. Irinotecan
180 mg m
72 was infused over 90 min. L-folinic acid 175 mg or d,l folinic acid 350 mg was given over 2 h followed by a bolus
of 5-ﬂuorouracil (400 mg m
72) and a 46 h continuous infusion of 5-ﬂuorouracil (2.4–2.8 g m
72). Forty-six previously
untreated patients (Group A) and 36 who had received 5-ﬂuorouracil for metastatic disease (Group B) were recruited.
Seventy-eight patients were evaluable for response. A partial response was seen in 13 out of 43 (30% [95%CI 28.1–31.9%])
in Group A and 8/35 (23% [95% CI 17.9–28.1%]) in Group B. 40% (95%CI 38.1–41.9%) of Group A and 26% (95% CI
20.9–31.1%) of Group B patients achieved disease stabilisation. The median progression free survival from the start of this
treatment was 7 months (95% CI 4.4–9.6 months) in Group A and 5 months (95% CI 2.8–7.2 months) in Group B. Median
overall survival was 14 months (95% CI 9.0–18.9) in Group A and 11 months (95% CI 5.9–16.1) in Group B. Grade 3–4
toxicity in both treatment groups were similar; leucopenia 17% and diarrhoea 7–8%. Grade 3–4 mucositis was not seen and
severe alopecia affected only three patients. IrMdG is an active and well-tolerated regimen for both the ﬁrst and second line
treatment of advanced colorectal cancer.
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Colorectal cancer is the second most common cause of cancer-
related death in Europe. For more than 40 years 5-ﬂuorouracil (5-
FU) has been the drug most commonly used to treat patients with
this disease. The response to this drug varies depending on whether
bolus or infusional chemotherapy is given. (Erlichman et al, 1988;
Advanced Colorectal Cancer Meta-Analysis Project, 1992) During
the last decade it has become clear that biomodulation with folinic
acid (FA) and alteration of the scheduling of 5-FU can signiﬁcantly
improve the response rate and toxicity proﬁle (de Gramont et al,
1997). Nevertheless, only about 20–30% of patients respond to 5-
FU based therapy (Skibber et al, 2001) and patients with metastatic
disease are not cured by chemotherapy. The topoisomerase I inhibi-
tor, irinotecan, usually given at a dose of 350 mg m
72 every 3 weeks
or 125 mg m
72 weekly for 4 out of 6 weeks, has shown activity in
patients with advanced colorectal cancer previously treated with 5-
FU. (Rothenberg et al, 1996; Rougier et al, 1998) Delayed onset diar-
rhoea, nausea and vomiting, neutropenia, fatigue and alopecia are
the main toxicities. Some patients experience an acute cholinergic
syndrome. There are now reports that have examined the combina-
tion of 5-FU and irinotecan. The combination of two drugs with
different modes of action has increased the response rate in
advanced colorectal cancer (Douillard et al, 2000; Saltz et al,
2000). However it is still not clear whether combinations of irinote-
can and 5-FU are best used in the ﬁrst or second line setting.
A ‘Modiﬁed de Gramont’ (MdG) regimen has been developed in
which a 2-h infusion of a ﬁxed dose of folinic acid is followed by
5-FU bolus then a high dose 46-h 5-FU infusion (de Gramont et
al, 1998; Andre ￿ et al, 1999). This regimen, alone or with oxalipla-
tin, has now been optimised (Maindrault-Goebel et al, 1999;
Cheeseman et al, 2002). MdG contains a higher dose of 5-FU than
the classical de Gramont schedule and avoids the need for hospital
attendance on 2 consecutive days. In this pilot study we have inves-
tigated a 2 weekly combination of irinotecan given at 180 mg m
72
together with MdG in the ﬁrst and second line setting. The new
regimen has been designated IrMdG.
The purpose of this non-randomised study was to investigate
the safety and efﬁcacy of IrMdG. It was designed as a pilot study
for MRC CR08 (FOCUS), a large randomised trial, now underway,
in which two of the experimental arms compare IrMdG in either
the ﬁrst or second line setting.
METHODS
Patients
From December 1998 to December 1999, following Institutional
Ethical Committee approval and with written informed consent,
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www.bjcancer.coma total of 82 patients were enrolled. Eligibility criteria were: locally
advanced or metastatic colorectal cancer; age 18–75 years; WHO
status of 1 or less with a life expectancy of more than 3 months;
satisfactory renal function (creatinine 1354mmol l
71); satisfactory
liver function (bilirubin41.56upper limit of normal (ULN),
transaminase456ULN); adequate haematological function
(haemoglobin510 g dl
71, absolute neutrophil count
52.0610
9 l
71 and platelets 5150610
9 l
71). In group A,
(n=46) patients were required to have measurable or evaluable
disease and not to have received any previous chemotherapy for
metastatic disease. Patients who had received adjuvant bolus 5-
FU/folinic acid were eligible provided chemotherapy had been
completed more than 6 months before entry into the study. In
group B (n=36), the same eligibility criteria applied except that
patients had only received 5-FU chemotherapy for metastatic
disease, and 4 weeks had to have elapsed since receiving their last
dose of 5-FU chemotherapy before entry into the study.
Statistical analysis
The primary endpoints were the safety and toxicity of this combi-
nation regimen. We were able to measure the outcome parameters
of response rate, progression-free and overall survival. Progression
free survival was deﬁned as the time from the start of treatment
until progression or death from disease, or unknown causes. The
analysis for toxicity assessment included all 82 patients. The analy-
sis for response criteria included the 78 evaluable patients. This was
a non-randomised study so no comparative statistics could be
applied. The survival curves are represented as Kaplan-Meier
Graphs.
STUDY DESIGN AND TREATMENT
All patients received irinotecan 180 mg m
72 over 90 min by infu-
sion followed by l-folinic acid 175 mg or d,l folinic acid 350 mg
intravenously over 2 h. A 5-min bolus dose of 5-FU
400 mg m
72 bolus was then given, followed by a continuous infu-
sion of 5-FU 2400–2800 mg m
72 over 46 h. The higher dose of 5-
FU was given to the ﬁrst four patients. Following two early deaths
the starting dose of 5-FU was reduced to 2400 mg m
72. All treat-
ments were given through a central venous line and repeated every
2 weeks. Response assessment took place after six cycles with clin-
ical examination, biochemical evaluation including CEA
(carcinoembryonic antigen) measurement and radiological evalua-
tion by computerised tomography or magnetic resonance
imaging. WHO response criteria were used. Patients with radiolo-
gically conﬁrmed stable or responding disease were offered a
further six cycles of treatment at 2 weekly intervals to commence
as soon as convenient. Patients were withdrawn from the study if
there was excessive toxicity, evidence of progressive disease or at
their request. Doses of both drugs were lowered, at the discretion
of the treating clinician if excessive toxicity was experienced by the
patient. At the end of the treatment period patients were followed
up according to local practice and any note of tumour progression
was made.
RESULTS
Patients and treatments
The characteristics of the 82 patients who met the eligibility criteria
for the respective groups are shown in Table 1. Figure 1 shows the
distribution of all treatment cycles received by the patients on both
groups of the study. The number of patients who received at least
six cycles of treatment was similar for both Groups of the study,
72% (33 out of 46) for Group A and 81% (29 out of 36) for Group
B. Progressive disease was the most common reason for not
completing at least six cycles. Three patients experienced severe
toxicity after only one cycle. The median number of treatment
cycles administered was 8 (range 1–12) for Group A and 7 (range
3–12) for Group B. Fifty-one per cent of those patients in Group
A and 41% of Group B patients who completed six cycles went on
to complete all 12 cycles.
Safety
Soon after the initiation of this study, two treatment-related deaths
occurred among four patients treated at the higher 5FU dose
(2800 mg m
72 46-h infusion). Neither death was clearly dose-
related: one patient developed diarrhoea and neutropenia but
remained at home without alerting professionals for several days
before being admitted moribund; the other was hospitalised with
neutropenia, which was beginning to recover when he died of an
unexplained cardiac event. Following these events the 5-FU dose
was reduced to 2400 mg m
72 46-h infusion for all subsequent
patients. The incidence of main toxic effects according to the
NCI-CTC grade scale are shown in Tables 2 and 3. Leucopenia
was the most common haematological toxicity. The rates of
neutropenia in both settings were similar. Four of the eight
patients in Group A with Grade 3–4 neutropenia required hospital
admission for neutropenic sepsis. This included the two toxic
deaths at the start of the study. Only one of seven affected patients
in Group B required hospital admission. Non-haematological toxi-
city was not severe in the majority of cases. No grade 3–4 alopecia
was seen in the ﬁrst line treatment group and only three patients
were affected in the second line treatment group. The incidence
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Table 1 Baseline characteristics
First line Second line
treatment group treatment group
(Group A) (Group B)
No of patients 46 36
Males : females 29 : 17 23 : 13
Age (range) years 57 (34–79) 58 (28–75)
Primary site:
Colon : Rectum 70 : 30 70 : 30
Sites of disease:
liver only 34% 50%
liver+other sites 35% 30%
lung only 6% 4%
peritoneum/retroperitoneum 9% 4%
other sites 16% 12%
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Figure 1 Distribution of treatment cycles received by all patients in the
study; ﬁrst-line treatment (Group A) and second line treatment (Group B).
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pine, was low compared with published toxicity data from
previous studies of single agent irinotecan (Douillard et al,
2000). One patient in Group B who experienced grade 3–4 diar-
rhoea required hospital admission. One other patient in Group B
required admission for rehydration following grade 3–4 nausea
and vomiting.
DOSE REDUCTIONS
Seven cycles of the higher dose of 5-FU (2800 mg m
72) were given
before the dose for all patients was reduced to 2400 mg m
72.
Overall, 69% (32 out of 46) of Group A patients did not require
a dose reduction, and reductions of 15–25% in both cytotoxic
drugs were sufﬁcient to keep toxicity within acceptable limits for
the remainder. Surprisingly, a greater proportion (83%) of Group
B patients was able to tolerate the regimen as second line treatment
without a dose reduction. However for the six requiring dose
reductions, two patients required a further dose reduction of both
drugs. For these patients, reducing the dose of both drugs to 65%
of full dose was sufﬁcient to allow treatment to continue.
RESPONSE RATE AND SURVIVAL
In total, 43 of the 46 patients in Group A were evaluable for
response. In addition to the two toxic deaths, there was one other
early death from a pulmonary embolism. One patient from Group
B developed a bowel ﬁstula and had to be withdrawn from the
study. A 30% partial response rate was seen in those patients
who had not previously been exposed to 5-FU. A response rate
of 23% occurred in those who received this regimen as second line
treatment. A larger proportion of patients treated in the ﬁrst line
setting achieved disease stabilisation: 40 vs 26% (Table 4).
Progression free survival was taken from the start of treatment
to the date of disease progression. Median progression-free survival
shown in Figure 2 was estimated to be 7 months (95% CI 4.4–9.6
months) in Group A and 5 months (95% CI 2.8–7.2 months) in
Group B. Overall survival (Figure 3) was taken from the date treat-
ment began to the date of death. To date, 15 patients are still alive.
Estimated median overall survival for Group A is 14 months (95%
CI 9.0–18.9) and for Group B is 11 months (95% CI 5.9–16.1
months).
DISCUSSION
Bimonthly infusional LV/5-FU (de Gramont regimen) has become
a widely accepted treatment with a higher response rate and lower
toxicity than bolus LV/5-FU (de Gramont et al, 1997). Modiﬁca-
tion of the de Gramont regimen with folinic acid and bolus 5-
FU given only on the ﬁrst day followed by a 46 h infusion of 5-
FU has potential advantages. Patients need to attend hospital only
on the ﬁrst day. This is more convenient for patients and it reduces
the hospital and drug costs. There is no consensus about the dose
of folinic acid and no evidence for a dose effect in relation to body
surface area for this regimen (Ychou et al, 1998). We therefore
used a ﬁxed dose consisting of a single vial on the ﬁrst day of each
cycle. Several modiﬁcations of the de Gramont regimen have been
described, and they appear to be as active as the classical regimen
(Seymour et al, 1998; de Gramont et al, 1998) although there has
been no randomised comparison.
Preclinical studies suggest that the combination of irinotecan
with 5-FU is synergistic. (Guichard et al, 1998) Combination
studies with the de Gramont regimen have established a 2 weekly
dose of irinotecan 180 mg m
72 is acceptable (Ducreux et al,
1999; Andre ￿ et al, 1999). Our study was designed to examine the
activity and toxicity of combining irinotecan and the modiﬁed
de Gramont regimen as ﬁrst- or second-line therapy of metastatic
colorectal cancer. The purpose was to deﬁne doses that could be
tested in randomised trials comparing combinations of irinotecan
and 5-FU, and oxaliplatin and 5-FU. Since the start of the study
it has become clear that irinotecan and 5-FU (de Gramont regi-
men) is active in the ﬁrst-line therapy of colorectal cancer. A
response rate of 34.8% on an intention to treat basis and 3.3
month prolongation in median survival was seen when irinotecan
was added to the 5-FU regimen (Douillard et al, 2000). The
response rate to IrMdG in our study was 30%, which was lower,
but the median progression-free survival was 7 months compared
to 6.7 months in the randomised trial (Douillard et al, 2000).
There was very little grade 3/4 non-haematological toxicity. Only
6–7% of patients experienced grade 3/4 diarrhoea and three
patients (8%) experienced grade 3/4 alopecia. This was much less
than the reported incidence of diarrhoea in the study by Douillard
et al (2000) However, in their trial, patients received either the
classical de Gramont regimen or a weekly high dose infusional 5-
FU regimen (Ko ¨hne et al, 1998). Grade 3/4 neutropenia was
17% with the modiﬁed de Gramont regimen, a little lower than
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Table 2 Haematological toxicity
AB
First line treatment Second line treatment
(n=46) (n=36)
Gd* 1/2 Gd* Gd* 1/2 Gd* 3/4
WBC 7 (15%) 8 (17%) 9 (25%) 6 (17%)
Hb 9 (20%) 2 (4%) 15 (42%) 1 (3%)
ANC 3 (6%) 8 (17%) 9 (25%) 6 (17%)
Platelets 0 0 1 (3%) 0
* NCI toxicity score. Total number of patient episodes of each of the respective
toxicities.
Table 4 Response rates
AB
First line treatment Second line treatment
(n=43) (n=35)
Partial response 13 (30%)* 8 (23%)
Stable disease 17 (40%) 9 (26%)
Disease progression 13 (30%) 18 (51%)
* 1 patient underwent resection of residual liver metastases.
Table 3 Non haematological toxicity
AB
Second line
First line treatment treatment
(n=46) (n=36)
Gd* 1/2 Gd* 3/4 Gd* 1/2 Gd* 3/4
Alopecia 18 (39%) 0 17 (47%) 3 (8%)
Diarrhoea 15 (33%) 3 (7%) 14 (39%) 2 (6%)
Nausea+vomiting 13 (28%) 4 (9%) 12 (33%) 2 (6%)
Mucositis 12 (26%) 0 14 (39%) 0
Constipation 2 (4%) 0 8 (22%) 0
Cholinergic syndrome 0 3 (7%) 0 3 (8%)
* NCI toxicity score. Total number of patient episodes of each of the respective
toxicities.
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reported by Andre ￿ et al (1999). The dose of 5-FU was initially
set at 2.8 g m
72 over 46 h as the FOLFIRI regimen reported by
Andre ￿ et al (1999) had used higher doses of 5-FU 2.4–3.0 g
m
72 in combination with irinotecan. The ﬁrst four patients
enrolled in our study received the higher dose of 5-FU and two
died on treatment. The ﬁrst developed neutropenia and diarrhoea,
which was not immediately reported. The second died suddenly
from a presumed cardiac arrhythmia while recovering from neutro-
penia. We therefore reduced the dose of 5-FU to 2.4 g m
72 and
did not encounter any further life- threatening haematological toxi-
city.
The second part of the study examined the combination in
second-line therapy. The expectation was that the regimen would
be less active and more toxic. This was not the case. The response
rate was lower at 23% but the median progression-free survival
measured from the start of treatment was similar (5 months).
Furthermore, 24 (68%) of the 36 enrolled patients had received
de Gramont style 5-FU as their previous regimen. In the UK at
this time the de Gramont regimen, or a continuous infusion of
5-FU was considered to be the optimal ﬁrst line regimen for
metastatic colorectal (Maughan et al, 2002). Other drugs, such
as oxaliplatin were unavailable. The pattern of haematological
and non-haematological toxicity was similar whether irinotecan
and the modiﬁed de Gramont regimen were given as ﬁrst or
second-line treatments. The emerging evidence from randomised
studies has suggested that combinations of irinotecan and 5-FU
should be used in the ﬁrst-line treatment of colorectal cancer
(Douillard et al, 2000; Saltz et al, 2000). However, the prolonga-
tion in median survival from the addition of irinotecan is small.
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Figure 2 Progression-free survival (PFS) and overall survival (OS) ﬁrst-line treatment group (Group A). Median PFS is 7 months (95% CI 4.3–9.6 months)
and OS is 14 months (95% CI 9.0–18.9 months).
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Figure 3 Progression-free survival and overall survival second-line treatment group (Group B). The median PFS is 5 months (95% CI 2.8–7.2 months)
and OS is 11 months (95% CI 5.9–16.1 months).
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second line setting still raises the question of the optimal use of
combinations of irinotecan and 5-FU. The patient cohort that
received this regimen in the second line setting had been
pretreated with the optimal combination of 5-FU and folinic acid
and their median event-free survival was still 5 months. During
this time oxaliplatin was not available to patients in the UK
who progressed on irinotecan. The Medical Research Council
Trial (CR08) (FOCUS- 5-FU, oxaliplatin, CPT-11, use and
sequencing) has been designed to address the question of the
optimum timing of combination therapies. Bolus 5-FU regimens
with irinotecan have been found to cause unexpected early deaths
in several National Cancer Institute sponsored co-operative
studies. An analysis of deaths in these trials has shown a three-
fold increase compared to non-irinotecan regimens (Rothenburg
et al, 2001). In our experience of IrMdG the toxicity is low
(Ledermann et al, 2001). The combination of drugs is active in
both the ﬁrst and second line setting and the regimen is now
being used as part of the MRC FOCUS trial.
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